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Purpose: To assess the safety and efﬁcacy of multiple injections of 0.5 and 2.0 mg conbercept using variable
dosing regimens in patients with neovascular age-related macular degeneration (AMD).
Design: Randomized, double-masked, multicenter, controlled-dose, and interval-ranging phase 2 clinical
trial divided into a 3-month loading phase followed by a maintenance phase.
Participants: Patients with choroidal neovascularization secondary to AMD with lesion sizes of 12 disc areas
or less and a best-corrected visual acuity (BCVA) letter score of between 73 and 24 were enrolled.
Methods: Patients were randomized 1:1 to receive either 0.5 or 2.0 mg intravitreal conbercept for 3
consecutive monthly does. After the third dose, each group was reassigned randomly again to monthly (Q1M
group) or as-needed (pro re nata [PRN] group) treatment without changing the drug assignment.
Main Outcome Measures: The primary end point was the mean change in BCVA from baseline to month 3,
with secondary end points being the mean change in BCVA, mean change in central retinal thickness (CRT), and
safety at month 12.
Results: We enrolled 122 patients. At the primary end point at month 3, mean improvements in BCVA from
baseline in the 0.5- and 2.0-mg groups were 8.97 and 10.43 letters, respectively. At month 12, mean improve-
ments in BCVA from baseline were 14.31, 9.31, 12.42, and 15.43 letters for the 0.5-mg PRN, 0.5-mg Q1M, 2.0-mg
PRN, and 2.0-mg Q1M regimens, respectively. At month 12, mean reductions in CRT in the 4 regimens were
119.8, 129.7, 152.1, and 170.8 mm, respectively. There were no signiﬁcant differences for the pairwise com-
parisons between all study groups. The difference in the number of injections between the 2 PRN groups was not
statistically signiﬁcant. Treatment with conbercept generally was safe and well tolerated.
Conclusions: The signiﬁcant gains in BCVA at 3 months were the same or better at 12 months in all con-
bercept dosing groups of neovascular AMD patients. During the 12 months, repeated intravitreal injections of
conbercept were well tolerated in these patients. Future clinical trials are required to conﬁrm its long-term efﬁcacy
and safety. Ophthalmology 2014;121:1740-1747 ª 2014 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
4Age-related macular degeneration (AMD) is a progressive
disease of the macula and the leading cause of irreversible
blindness in industrialized countries.1 Although it has not yet
become the leading cause of blindness among the Chinese
population, the prevalence of AMD is rising gradually as
the population ages and the socioeconomic situation
improves.2 An epidemiologic investigation showed that
15.5% of the included Shanghai residents (50 years of
age) had AMD and 11.9% of them had neovascular
(exudative) AMD.3 Neovascular AMD is characterized by
the growth of abnormal new blood vessels under the retinal
pigment epithelium, under the retina, or within the retina.
When neovascularization arises from the choroid, these new
blood vessels are referred to as choroidal neovascularization1740  2014 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). Published by Elsevier Inc(CNV). The pathophysiologic features of neovascular
AMD are not fully understood, but it is known that vascular
endothelial growth factor (VEGF) plays an important role in
the proliferation and maintenance of this neovascularization.
This fact has led to the development of therapeutic
strategies to inhibit VEGF for the treatment of neovascular
AMD.5
Between 2004 and 2006, three anti-VEGF drugs were
introduced to ophthalmology after either receiving regula-
tory approval for the treatment of AMD or being used in an
off-label manner. They exhibit important differences in their
sites of activity, formulation methods, binding afﬁnities, and
biologic activities. Pegaptanib (Macugen; Eyetech Pharma-
ceuticals, Lexington, MA) is a ribonucleic acid aptamer that.
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VEGF165) and larger isoforms of VEGF by attaching to its
heparin binding domain,6 whereas ranibizumab (Lucentis;
Genentech, Inc., South San Francisco, CA) and
bevacizumab (Avastin; Genentech and Roche, Basel,
Switzerland) are derived from a murine monoclonal
antibody against VEGF-A; ranibizumab is an afﬁnity-
matured, humanized, monoclonal antigen binding fragment
from the antibody and bevacizumab is a full-length,
humanized, monoclonal antibody directed against VEGF-
A. Both drugs function by blocking the same receptor
binding domains of all VEGF-A isoforms.7 In November
2011, aﬂibercept (Eylea; Regeneron, Tarrytown, NY; and
Bayer, Leverkusen, Germany) was approved by the US
Food and Drug Administration. This soluble decoy
receptor is produced by combining all-human DNA se-
quences of the second binding domain of human VEGF
receptor (VEGFR)-1 to the third binding domain of human
VEGFR-2, which is then combined with the Fc region of
human immunoglobulin G-1.8 Aﬂibercept binds to all
VEGF-A and VEGF-B isoforms, as well as to the highly
related placental growth factor.
Similar to aﬂibercept, conbercept (KH902; Chengdu
Kanghong Biotech Co., Ltd., Sichuan, China) consists of the
VEGF binding domains of the human VEGFR-1 and
VEGFR-2 combined with the Fc portion of the human
immunoglobulin G-1. In addition to having high afﬁnity for
all isoforms of VEGF-A, it also binds to placental growth
factor and VEGF-B. The structural difference between
conbercept and aﬂibercept is that conbercept also contains
the fourth binding domain of VEGFR-2. This fourth domain
is essential for receptor dimerization and enhances the as-
sociation rate of VEGF to the receptor.9,10 Because this
domain of VEGFR-2 has a lower isoelectric point, the
addition of this domain to KH902 decreases the positive
charge of the molecule and results in decreased adhesion to
the extracellular matrix. Preclinical studies have demon-
strated that conbercept shows strong antiangiogenetic effects
by binding with high afﬁnity and neutralizing VEGF-A, all
its isoforms, and placental growth factor.11
Intravitreal administration of conbercept has been shown
to successfully prevent lesion growth and leakage of CNV
in a nonhuman primate model.11,12 A phase 1 study also
demonstrated that conbercept resulted in improvements in
best-corrected visual acuity (BCVA), reduction in central
retinal thickness (CRT), and a decrease in the area of CNV
in patients with neovascular AMD.13 The present study was
designed to investigate the safety and efﬁcacy of intravitreal
injections of conbercept in patients with CNV secondary to
AMD.Methods
Study Design
The AURORA study was a 12-month, randomized, double-
masked, controlled-dose, and interval-ranging phase 2 clinical
trial and was designed as a superiority trial to assess the safety and
efﬁcacy of different dosing regimens of conbercept in patients with
CNV secondary to AMD. At 9 sites in China, the safety andefﬁcacy of different doses and different dosing regimens were
compared after repeated intravitreal injections of conbercept. The
primary end point was assessed at month 3, and the results of the
maintenance phase were assessed at month 12. The major eligi-
bility criteria included age 50 years or older, the presence in the
study eye (1 eye per patient) of untreated active subfoveal or
juxtafoveal CNV secondary to AMD, lesion size 12 disc areas or
less in either eye, and BCVA letter scores in the study eye between
73 and 24. The BCVA score was based on the number of letters
read correctly on the Early Treatment Diabetic Retinopathy Study
visual acuity chart when assessed at a starting distance of 4 m. An
Early Treatment Diabetic Retinopathy Study visual acuity score of
73 to 24 letters is approximately 20/40 to 20/320 in Snellen visual
acuity. An increase in the BCVA letter score indicates improve-
ment in visual acuity. Patients were excluded if any of the
following were present: signiﬁcant subfoveal atrophy or scarring;
presence of other causes of CNV in either eye; history of previous
AMD drug treatment (such as anti-VEGF drugs and steroids);
previous laser therapy or other ocular operation, or both, in the
study eye, such as macular translocation surgery, cataract surgery,
vitrectomy surgery, glaucoma ﬁltering operation, verteporﬁn
photodynamic therapy, subfoveal focal laser photocoagulation, and
transpupillary thermotherapy; active ocular inﬂammation or
infection; uncontrolled diabetes mellitus; uncontrolled hyperten-
sion; history of cerebrovascular accident or myocardial infarction
within 6 months; renal failure requiring dialysis or renal transplant;
pregnancy or lactation; or history of allergy to ﬂuorescein or
povidone iodine. The trial was registered at www.
clinicaltrial.gov under the identiﬁer NCT 01157715.
Intervention
Eligible patients were randomized 1:1 to 0.5- or 2.0-mg treatment
groups. Initially, all patients received monthly intravitreal in-
jections of conbercept for a total of 3 injections. After the 3-month
loading phase, patients were reassigned randomly to monthly
(Q1M group) or as-needed treatments (pro re nata [PRN] group)
with the same dose of conbercept given during the loading phase.
Patients randomized to the monthly regimen were treated
monthly during the maintenance phase. Patients randomized to the
PRN regimen were not re-treated unless any of the following was
present in the study eye: a more than 100-mm increase in CRT
compared with the lowest previous measurement; a loss of 5 or
more BCVA letters compared with the best previous measurement;
new, recurrent, or persistent subretinal or intraretinal ﬂuid based on
the review of all the optical coherence tomography (OCT) scans;
new onset of classic neovascularization; new or persistent leakage
on ﬂuorescein angiography (FA); or new macular hemorrhage or
hemorrhagic area of more than 50% of the disc area. Decisions
about re-treatment were made on the basis of the investigator’s
evaluation of the BCVA, ophthalmic examination results, and
images from OCT, FA, and fundus photography (FP). The inves-
tigator was masked to the assignment of dose in the PRN arms.
Rescue therapy with another treatment was not offered as part of
this study, so if a patient elected to receive any other therapy for
their neovascular AMD, then they were asked to exit the study. The
only approved anti-VEGF therapy in China is ranibizumab, and
ranibizumab was not approved in China until 2012, which occurred
well after the start of this study in 2010.
The study was conducted in accordance with the Declaration of
Helsinki and its subsequent amendments, China good clinical
practice regulations, and applicable institutional regulatory re-
quirements. Before the initiation of the study, relevant institutional
review boards and ethics committees from the respective study
centers approved the research protocol and its amendments. All
patients provided written informed consent for study participation.1741
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All patients were evaluated monthly. Evaluations included visual
function, ocular assessments, adverse events using BCVA
measured with the Early Treatment Diabetic Retinopathy Study
chart (4-m starting distance), intraocular pressure measurements,
slit-lamp examinations, and imaging with FP, OCT, FA,
and indocyanine green angiography (ICGA). Fundus photography
and OCT imaging were performed at every visit, whereas FA and
ICGA were performed only at baseline and at months 3, 8, and
12. Optical coherence tomography was performed either with the
Stratus OCT instrument (Carl Zeiss Meditec, Dublin, CA) or the
Heidelberg Spectralis spectral-domain OCT instrument (Heidel-
berg Engineering, Heidelberg, Germany). The same type of OCT
instrument used at baseline was used throughout the study. When
the Stratus OCT was used, the following scan patterns were
performed on both eyes and were centered on the fovea: two 7-
mm posterior pole custom scans positioned 5 below horizontal
from the temporal edge of the optic nerve toward the fovea (512
A-scans per B-scan), one 3-mm high-resolution cross-hair scan
(512 A-scans per B-scan), one 6-mm high-resolution cross-hair
linear scan (512 A-scans per B-scan), and 2 fast macular thickness
map scans consisting of 6 radial linear scans (128 A-scans per
B-scan). When the Heidelberg Spectralis spectral-domain OCT
was used, the following scan patterns were performed on both
eyes and were centered on the fovea: a single 30 horizontal
section scan with an automatic real-time setting of 15 (1536
A-scans per B-scan) and a volume scan over a 2020 area
consisting of 49 B-scans (512 A-scans per B-scan), with each B-
scan separated by 120 mm, and an automatic real-time setting of
15. Either the Topcon TRC.50-DX or the Heidelberg HRA2 were
used to perform FA and ICGA. Fundus photography was per-
formed using the Topcon TRC.50-DX, Topcon TRC-50EX, and
Zeiss FF 450 plus. The OCT, FA, ICGA, and FP images were
graded at a central reading center (the Digital Angiography
Reading Center, New York, NY). Adverse events (AEs) were
recorded at each visit as well. Study visits were scheduled every
307 days.Figure 1. Diagram of participant ﬂow in the AURORA study. Before the secon
monthly (Q1M) and 2.0-mg Q1M groups, respectively. At the end of maintenan
discontinued the study in the 0.5-mg Q1M, 0.5-mg as-needed (pro re nata [PR
patients were included in the ﬁnal analysis.
1742Outcomes
The primary efﬁcacy outcome was the mean change in BCVA
score from baseline at month 3. Secondary outcomes at month 12
were the mean changes of BCVA score from baseline over time,
the incidence rates of AEs over time, the mean changes in CRT on
OCT imaging over time, the changes in leakage area on FA im-
aging, and the mean number of injections over time.
Statistical Methods
The full analysis dataset with all the patients who completed the
month 12 visit was the dataset used for the primary efﬁcacy
analysis. Mean changes in BCVA from baseline at months 3 and
12 were assessed using the paired t test or rank-sum test with 95%
conﬁdence intervals. The chi-square test or Fisher test was used for
the proportions of patients who gained more than 0 letters, gained
at least 15 letters, and gained at least 30 letters or lost fewer than 15
letters. Other secondary end points, as well as demographic data at
baseline, were evaluated using summary statistics.
The safety analysis set with all the patients who participated in
the study was used for all safety and tolerability assessments. All
the AEs, treatment-related AEs, incidence of AEs, and serious
AEs (SAEs) were compared between groups using the chi-square
test or Fisher exact method. All statistical tests were 2-sided. A
P value less than 0.05 was considered statistically signiﬁcant. All
the above analyses were performed using SAS software version 9.1
(SAS Inc., Cary, NC). Adverse events were coded with the Med-
ical Dictionary for Regulatory Activities (MedDRA 14.1; the In-
ternational Federation of Pharmaceutical Manufacturers and
Associations [IFPMA], Geneva, Switzerland).
Results
Characteristics of Patients
Between July 2010 and July 2012, 122 patients (0.5-mg group, n ¼
60; 2.0-mg group, n ¼ 62) were randomized. One patient withdrewd randomization, 5 (8.3%) and 6 (9.7%) patients withdrew from the 0.5-mg
ce phase, 3 (10.3%), 2 (7.7%), 1 (3.3%), and 0 (0%) patients prematurely
N]), 2.0-mg Q1M, and 2.0-mg PRN groups, respectively. A total of 102
Table 1. Baseline Characteristics of the Study Population
Characteristics
0.5-mg Group 2.0-mg Group
As Needed (n ¼ 26) Monthly (n ¼ 29) As Needed (n ¼ 26) Monthly (n ¼ 30)
Age (yrs) 64.508.89 69.668.26 66.089.27 63.537.55
Sex, no. (%)
Male 13 (50.0) 19 (65.5) 16 (61.5) 22 (73.3)
Female 13 (50.0) 10 (34.5) 10 (38.5) 8 (26.7)
Study eye, no. (%)
Right eye 14 (53.9) 13 (44.8) 15 (57.7) 17 (56.7)
Left eye 12 (46.2) 16 (55.2) 11 (42.3) 13 (43.3)
BCVA (letters) 46.5814.54 50.7912.87 47.6213.73 48.8714.66
CRT (mm) 291.54183.35 310.90138.45 330.36121.24 335.50152.39
CNV type, no. (%)
Occult 5 (19.2) 12 (41.4) 10 (38.5) 7 (23.3)
Classic 4 (15.4) 6 (20.7) 5 (19.2) 5 (16.7)
Predominant classic 17 (65.4) 11 (37.9) 11 (42.3) 18 (60.0)
CNV area (mm2) 8.078.07 8.406.14 9.756.50 7.746.91
Fluorescein leakage, no. (%)
Yes 26 (100.0) 29 (100.0) 26 (100.0) 30 (100.0)
No 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Leakage area (mm2) 8.307.87 9.316.28 10.947.02 8.266.74
BCVA ¼ best-corrected visual acuity; CRT ¼ central retinal thickness; CNV ¼ choroidal neovascularization.
Data are mean  standard deviation unless otherwise indicated.
Li et al  Conbercept for Neovascular AMDconsent after the randomization and 1 patient was found to have
angioid streaks, which was a condition among the exclusion
criteria, leaving 120 patients who were treated and included in our
analyses. Of these, 114 patients completed treatment in the
3-month loading phase. Reasons for withdrawal included an SAE
(n ¼ 1, reduced visual acuity score from 40 to 5), investigator
decisions (n ¼ 2), protocol deviation (n ¼ 1), an inability to attend
visits (n ¼ 1), and a subject’s request (n ¼ 1). Before the second
randomization, 3 patients exited the study. One withdrew consent
and 2 had ocular AEs that included ocular inﬂammation and vit-
reous opacities, leaving 111 patients to continue treatment in the
maintenance phase. Overall, 105 patients (86.1%) completed the
12-month study period (0.5-mg PRN, n ¼ 24; 0.5-mg Q1M, n ¼
26; 2.0-mg PRN, n ¼ 26; 2.0-mg Q1M, n ¼ 29; Fig 1). The
reasons why the 6 patients exited before the ﬁnal month 12 visit
included SAEs (n ¼ 3; including 1 case of suspected drug-
induced hepatitis, 1 case of hepatitis B, and 1 hepatic tumor), an
investigator decision (n ¼ 1; AMD progress in the fellow eye), an
inability to attend visits (n ¼ 1), and a subject’s request (n ¼ 1).
During the entire study, 10 patients were deemed ineligible
because of protocol deviations. Eight of them failed to meet the
study eye inclusion criteria, and the other 2 did not meet nonocular
inclusion criteria. Overall, the randomized groups were well
balanced with respect to baseline demographics and study eye
characteristics (Table 1).Table 2. Best-Corrected Visual Acuit
Time Point 0.5-mg Group
Month 3
BCVA (letters) 58.3917.30
Change from BSL (letters) 8.9713.08
Month 12 As Needed (n ¼ 26) Monthly (n ¼ 29) To
BCVA (letters) 60.8817.42 60.1017.52 59
Change from BSL (letters) 14.3117.07 9.3110.98 10
BCVA ¼ best-corrected visual acuity; BSL ¼ baseline.
Data are mean  standard deviation.Efﬁcacy
Treatment with conbercept produced signiﬁcant improvements in
BCVA in all treatment groups at both month 3 (the primary end
point) and month 12 (Table 2). Most of the improvement occurred
during the loading phase in the ﬁrst 3 months. The mean changes
in BCVA from baseline at month 3 were 8.9713.08 letters for the
0.5-mg group (P<0.0001) and 10.4310.65 letters for the 2.0-mg
group (P<0.0001). Furthermore, these improvements were main-
tained or increased during the study. At month 12, mean changes in
BCVA were 14.3117.07 letters (0.5-mg PRN; P ¼ 0.0002),
9.3110.98 letters (0.5-mg Q1M; P<0.0001), 12.4216.39 letters
(2.0-mg PRN; P ¼ 0.0007), and 15.4314.70 letters (2.0-mg
Q1M; P<0.0001) compared with baseline (Fig 2). The visual
outcomes from the 2 dosing regimens were compared along with
visual outcomes from all the study groups. No signiﬁcant
differences were observed between the dosing regimens and all
study groups using pairwise comparisons (P>0.05).
At month 12, the proportions of patients gaining 15 letters or
more were 50.0%, 31.0%, 42.3%, and 46.7% for the 0.5-mg PRN,
0.5-mg Q1M, 2.0-mg PRN, and 2.0-mg Q1M groups, respectively.
At month 12, the proportions of eyes losing fewer than 15 letters
were 100.0%, 96.55%, 96.15%, and 100.0%, respectively (Fig 3).
Improvements in BCVA with conbercept treatment were
associated with a decrease in CRT measured with OCT imaging.y Outcomes at Months 3 and 12
2.0-mg Group
59.4616.13
10.4310.65
tal (n ¼ 55) As Needed (n ¼ 26) Monthly (n ¼ 30) Total (n ¼ 56)
.9218.82 60.0418.54 64.3016.37 62.6417.12
.4915.99 12.4216.39 15.4314.70 13.6114.97
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Figure 2. The mean change in best-corrected visual acuity (BCVA) from
baseline over time in patients in the 4 dosing regimen treatment groups
through 12 months. PRN ¼ pro re nata (as needed); Q1M ¼ monthly.
Figure 4. Themean change in central retinal thickness (CRT) from baseline
over time using the 4 dosing regimens through 12 months. The CRT reduced
rapidly during the ﬁrst 3-month loading phase and then continued to decrease
through month 12. PRN ¼ pro re nata (as needed); Q1M ¼ monthly.
Ophthalmology Volume 121, Number 9, September 2014The CRT decrease observed at month 3 continued to decrease
through month 12. By month 12, the mean CRT measurements had
decreased by 116.0194.84 mm (0.5-mg PRN; P ¼ 0.0056),
131.6180.42 mm (0.5-mg Q1M; P ¼ 0.0005), 157.8183.98 mm
(2.0-mg PRN; P ¼ 0.0003), and 168.7185.47 mm (2.0-mg Q1M;
P<0.0001) for each group, respectively (Fig 4; Table 3).
The reductions of leakage area, CNV area, and lesion size on
FA compared with baseline were statistically signiﬁcant (Fig 5).
All types of neovascular AMD (classic, occult, and
predominantly classic lesions) were included in the study, and
after 12 months of treatment, there were no signiﬁcant
differences between the 4 dosing groups with respect to changes
in the lesions (P>0.05).
Over the maintenance phase, the mean numbers of conbercept
injections at 12 months were 4.73 (0.5-mg PRN group), 8.34 (0.5-
mg Q1M group), 4.88 (2.0-mg PRN group), and 8.57 (2.0-mg
Q1M group). The 0.5-mg PRN group had 3.6 fewer injections
than the 0.5-mg Q1M group, and the 2.0-mg PRN group had 3.7
fewer injections than the 2.0-mg Q1M group. The study results
conﬁrmed that the PRN groups received signiﬁcantly fewer in-
jections than the Q1M groups (P<0.05). The difference in the
number of injections and the difference in the improvement of
BCVA between both PRN groups were not statistically signiﬁcant
(P>0.05).
Safety
Intravitreal conbercept was well tolerated. The most common
ocular AEs that occurred were associated with intravitreal in-
jections such as transient increased intraocular pressure, vitreous
ﬂoaters, cataract, conjunctival hemorrhage, and cornealFigure 3. The number of patients with change in best-corrected visual
acuity (BCVA) from baseline at month 12 in the 4 dosing regimens.
PRN ¼ pro re nata (as needed); Q1M ¼ monthly.
1744inﬂammation. Most AEs were reported as mild or moderate and
disappeared with or without treatment. During the entire study
period, 39 patients (66.1%) in the 0.5-mg group reported AEs,
which included 4 (6.78%) related to the study drug, 11 (18.64%)
associated with intravitreal injections, and 7 (11.86%) SAEs; 45
patients (73.77%) in the 2.0-mg group reported AEs, which
included 4 (6.56%) related to the study drug, 17 (27.87%) asso-
ciated with intravitreal injection, and 3 (4.92%) SAEs.
During the maintenance phase, the incidence rates of ocular
AEs in the study eyes were 23.1%, 20.7%, 27.0%, and 30.0% for
the 0.5-mg PRN, 0.5-mg Q1M, 2.0-mg PRN, and 2.0-mg Q1M
groups, respectively. The group with the highest exposure, the 2.0-
mg Q1M group, also had the highest rate of AEs. However,
because of the limited sample size, this phase 2 study was not
powered adequately to assess the signiﬁcance of these differences
in AEs among the treatment groups. The SAEs affecting study eyes
were uncommon in all treatment groups. One patient in the 0.5-mg
PRN group received cataract extraction and intraocular lens im-
plantation using phacoemulsiﬁcation because of cataract progres-
sion with reduction in BCVA (compared with baseline) during the
study. The patient recovered well after surgery and did not exit the
study. One patient in the 2.0-mg Q1M group was hospitalized after
the last injection because of pain in the study eye, a decrease of 7
letters in BCVA (decreased by 65 letters compared with baseline),
foreign body sensation, and vitreous opacity. This patient under-
went a tap for presumed endophthalmitis, and although the bac-
terial culture results were negative, this patient was diagnosed
clinically with infectious endophthalmitis and received antibiotic
therapy. After the antibiotic therapy, the symptoms of inﬂamma-
tion dissipated, with a concomitant gradual improvement in
BCVA. By the last study visit, the BCVA was restored to 70 let-
ters, and the cornea and lens were clear. The investigators judged
that both SAEs might have been related to treatment. In addition, 2
patients experienced visual acuity decreases of more than 30 letters
(compared with the last assessment of BCVA before the most
recent treatment). One case occurred in the nonstudy eye. The other
one occurred in the study eye during the loading phase with the
0.5-mg dose, and the investigator thought it was in the patient’s
best interest to exit the study.
No systematic (nonocular) AE was judged by the investigators
to be related to the study drug or to the study procedure. No events
described by the Antiplatelet Trialists’ Collaboration occurred
during the study. There were no cardiovascular or cerebrovascular
events such as heart failure, stroke, or arterial thrombosis. There
were no apparent allergic reactions, and there were no deaths
during the study period. All SAEs, the frequent study drugerelated
AEs, and the study procedureerelated AEs are summarized in
Table 4.
Table 3. Outcomes after the Maintenance Phase at Month 12
Outcomes
0.5-mg Group 2.0-mg Group
As Needed (n ¼ 26) Monthly (n ¼ 29) As Needed (n ¼ 26) Monthly (n ¼ 30)
Increase of 30 letters, no. (%) 4 (15.4) 0 (0) 3 (11.5) 6 (20.0)
Increase of 15e29 letters, no. (%) 9 (34.6) 9 (31.0) 8 (30.8) 8 (26.7)
Increase of 0e14 letters, no. (%) 6 (23.1) 14 (48.3) 10 (38.5) 13 (43.3)
Decrease of 1e14 letters, no. (%) 7 (26.9) 5 (17.2) 4 (15.4) 3 (10.0)
Decrease of 15 letters, no. (%) 0 (0) 1 (3.4) 1 (3.8) 0 (0)
Change of CRT from BSL (mm) 119.8175.50 129.7170.80 152.1142.73 170.8160.43
Change in leakage area (mm2) 3.085.94 4.765.90 7.297.17 4.414.82
Change in CNV area (mm2) 2.856.03 3.865.87 6.115.99 3.885.21
Change in lesion size (mm2) 2.565.31 3.225.18 5.715.57 4.125.77
No. of injections 7.73 11.34 7.88 11.57
BSL ¼ baseline; CRT ¼ central retinal thickness; CNV ¼ choroidal neovascularization.
Data are mean  standard deviation unless otherwise indicated.
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In the AURORA study, multiple intravitreal injections of
conbercept resulted in a signiﬁcant rapid increase of BCVA
and a reduction of CRT, lesion area, and leakage in eyes of
patients with neovascular AMD. Within the ﬁrst 3 months,
improvements in BCVA were evident after the 3 loading-
dose injections in the 0.5- and 2.0-mg groups, and these
improvements were maintained or increased throughFigure 5. The mean changes in (A) leakage area, (B) area of choroidal neo
angiography, from baseline in patients with 4 dosing regimens at months 3 and12 months by using a variable dosing regimen or ﬁxed
monthly dosing (0.5 mg PRN, 0.5 mg Q1M, 2.0 mg PRN,
and 2.0 mg Q1M).
The improvements in BCVA and anatomic outcomes in
the 4 treatment groups were statistically signiﬁcant when
compared with baseline, but there were no statistically sig-
niﬁcant differences between the 2 doses (0.5 and 2.0 mg) or
the 2 dosing regimens (Q1M and PRN). In addition, there
were no signiﬁcant differences between dose and regimenvascularization (CNV), (C) and lesion size, determined using ﬂuorescein
12. PRN ¼ pro re nata (as needed); Q1M ¼ monthly.
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Table 4. Serious Adverse Events and Most Frequent Treatment-
Related Adverse Events during the Study
SAEs/AEs 0.5-mg Group 2.0-mg Group
SAEs, no. (%)
Ocular
Reduced visual acuity* 2 (3.39)y 0
Cataract progression 1 (1.69) 0
Endophthalmitis 0 1 (1.64)
Systemic
Suspected drug-induced hepatitis 1 (1.69) 0
Hepatitis B 1 (1.69) 0
Hepatic tumor 0 1 (1.64)
Pneumonia 1 (1.69) 0
Emphysema 1 (1.69) 0
Prostate tumor 1 (1.69) 0
Benign prostatic hyperplasia 1 (1.69) 1 (1.64)
Cystitis 1 (1.69) 0
AEs, no. (%)
Conjunctival hemorrhage 7 (11.86) 5 (8.20)
Reduced visual acuityz 6 (10.17) 3 (4.92)
Vitreous opacity 1 (1.69) 3 (4.92)
Increased intraocular pressure 0 4 (6.56)
Conjunctivitis 1 (1.69) 3 (4.92)
AMD 3 (5.08) 0
Cataract progression 1 (1.69) 2 (3.28)
Corneal epithelial defect 0 2 (3.28)
Retinal hole 0 2 (3.28)
Ocular inﬂammation 1 (1.69) 0
Iritis 0 1 (1.64)
Retinal tear 0 1 (1.64)
AE ¼ adverse event; AMD ¼ age-related macular degeneration; SAE ¼
serious adverse event.
*Causes a decrease of 30 letters in visual acuity (compared with the last
assessment of visual acuity before the most recent treatment) lasting more
than 1 hour.
yOne case occurred in the study eye, and the other occurred in the non-
study eye.
zA decrease of <30 letters in visual acuity compared with baseline.
Ophthalmology Volume 121, Number 9, September 2014with respect to the changes in the neovascular lesions. This
suggests that either dose or treatment regimen was similarly
efﬁcacious.
Overall, the administration of conbercept over the course
of the study generally was consistent with the number of
treatments that had been planned, indicating good compli-
ance with the protocol. In the PRN groups, injections were
given after month 3 in the maintenance phase when certain
re-treatment criteria were met. The numbers of injections
were similar in the 0.5-mg PRN (4.73) and 2.0-mg PRN
(4.88) groups during this maintenance phase. When the 3
mandatory injections during the ﬁrst 3 months are included,
the 0.5- and 2.0-mg PRN groups received 7.73 and 7.88
injections, respectively. These numbers are similar to the
mean number of treatments in the PRN arms of the
Comparison of AMD Treatments Trials, which were 6.9
for ranibizumab and 7.7 for bevacizumab at 1 year.14
In the phase 1 study of conbercept, there was a mean
improvement in BCVA of 19.6 letters by day 42 after a
single intravitreal injection of 6 escalating doses. No patient
exhibited a decline in visual acuity during the course of
study, whereas 85.7% of patients gained visual acuity. At
day 42, there was a mean decrease in CRT of 77.2 mm. The1746results from the AURORA study conﬁrmed these earlier
beneﬁts from the phase 1 study and demonstrated that the
beneﬁts of intravitreal injections of conbercept could be
maintained for at least 12 months.
During the AURORA study, all digital images fromOCT,
FA, ICGA, and FP were sent to the independent masked
central reading center known as the Digital Angiography
Reading Center for analyses. Other studies, such as the
EXCITE (the Efﬁcacy and Safety of Ranibizumab in Patients
With Subfoveal Choroidal Neovascularization [CNV]
Secondary to Age-related Macular Degeneration [AMD])
study,15 which used ranibizumab, and the phase 116 and
phase 2 (CLinical Evaluation of Anti-angiogenesis in the
Retina Intravitreal Trial [CLEAR-IT 1])17 studies, which
used aﬂibercept, used the Digital Angiography Reading
Center as well. As a result, the image analyses performed
in the AURORA (Assess the safety and efﬁcacy of KH902
in patients with sUbfoveal choroidal neovasculaRization
secOndary to age-Related mAcular degeneration) study
were of the same standard as those in these other studies.
Overall, conbercept was well tolerated, and the incidence
of ocular AEs was low. The most common AEs usually
were caused by the intravitreal injection procedure and
disappeared with or without treatment. The common intra-
ocular and systemic AEs associated with conbercept also
occurred with other similar anti-VEGF products,14,17 such
as the incidence of endophthalmitis, iritis, and decreased
visual acuity. The SAEs, such as retinal detachment or
laceration, that were reported with other similar products did
not occur in this study. No systemic AEs or SAEs were
related to the study treatment. However, a case of hepatitis
suspected as being drug induced was identiﬁed and thought
to be caused by an oral supplement (speciﬁc name un-
known), and the hepatitis was categorized as having no
relationship with the study drug. Because of the limited
number of participants in the AURORA study, as well as
the absence of a control group, the true incidence of ocular
and nonocular AEs requires a larger randomized trial for
accurate assessment.
In conclusion, the results of the AURORA study
demonstrated statistically signiﬁcant visual acuity and
anatomic beneﬁts from repeated intravitreal injections of
conbercept at 3 months (primary outcome) in both dosing
groups (0.5 and 2.0 mg), and these outcomes were main-
tained or improved further by using different dosing regi-
mens (Q1M and PRN) through 12 months. These favorable
outcomes were achieved while maintaining an acceptable
AE proﬁle. Conbercept seems to be a promising intravitreal
drug for the treatment of CNV secondary to AMD, and
phase 3 trials are underway.
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